 |
FDA Approval Activities for this Drug
Lumigan (bimatoprost ophthalmic solution), 0.03%, Allergan, NDA 21-275/S10 & S12 8/25/03 8/28/03 8/28/03
Lumigan (bimatoprost ophthalmic solution), 0.03%, Allergan, NDA 21-275/S6 8/26/02 8/30/02 8/26/02
Lumigan (bimatoprost ophthalmic solution), 0.03%, Allergan, NDA 21-275 3/16/01 4/19/01 8/20/01
Lumigan Indications: for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive [failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication. Lumigan (bimatoprost ophthalmic solution), Allergan,
For the most up-to-date approval information, please locate this API using the drug index.
|